News and views

THE New Year's Honours List contains the names of the following men of science and others associated with scientific work: Baron: Sir Ernest Rutherford, chairman of the Advisory Council of the Committee of the Privy Council for Scientific and Industrial Research, and until recently president of the Royal Society. Baronets: Sir John Rose Bradford, president of the Royal College of Physicians; Sir Richard Gregory, editor of NATURE. K.C.B.: Dr. F. E. Smith, secretary to the Committee of the Privy Council for Scientific and Industrial Research. K.C.M.G.: Hon. Sir Walter Hartwell James, Chancellor of the University of Western Australia; Dr. A. W. Hill, Director of the Royal Botanic Gardens, Kew. Knights: Prof. C. R. Beazley, professor of medieval and modern history in the University of Birmingham; Mr. W. W. Hornell, Viee-Chancellor of Hong Kong University; Dr. E. G. Graham Little, member of Senate of the University of London since 1906; Dr. R. W. Livingstone, Vice-Chancellor of the Queen's University, Belfast. C.B.: Mr. R. L. Hobson, Keeper of Ceramics and Ethnography, British Museum. C.I.E.: Lieut.—Col. H. W. Acton, director of the School of Tropical Medicine and Hygiene, Calcutta. C.B.E.: Miss Caroline Haslett, director of the Electrical Association for Women and secretary of the Women's Engineering Society (Inc.); Miss Edith Helen Major, Mistress of Girton College, Cambridge; Miss Louisa Martindale, president of the Medical Women's Federation and vice-president of the Medical Women's International Association; Prof. Sidney Russ, professor of physics, Medical School, Middlesex Hospital, for work in connexion with radium; Mr. J. J. Shaw, secretary to the Seismological Investigations Committee of the British Association. O.B.E.: Dr. W. M. Aders, lately economic biologist, Zanzibar; Mr. R. S. Capon, Superintendent of Scientific Research, Royal Aircraft Establishment, Air Ministry; Mr. J. M. Carey, H.M. Divisional Inspector of Mines; Mr. J. S. Corbett, secretary of the Empire Forestry Association; Mr. A. de V. Wade, principal assistant in the Native Affairs Department, Kenya. M.B.E.: Dr. V. E. Wilkins, Assistant Principal, Ministry of Agriculture and Fisheries.

Smith+Nephew, the global medical technology business, announced the launch of CORI◊ handheld robotics, an advanced system for both total and partial knee arthroplasties.
The CORI system is a compact and fully mobile5 solution incorporating a 3-D intra-operative imaging system with an advanced robotic sculpting tool. The robotic system allows surgeons to measure, plan, and perform a knee surgery which is personalised to the patient's individual anatomy in theatre.
The Smith+Nephew system is considerably more compact than alternative robotic systems, has minimal set up time, and is so portable, it can be moved from theatre to theatre to optimise flow of patients through surgical units.
One of the first surgeons to use the device in the UK, Mr. Tim Parratt, Consultant Orthopaedic Surgeon at East Suffolk North Essex NHS Foundation Trust says, "The CORI system is excellent to use. This technology is mobile, portable and slots seamlessly into theatre. There is minimal disruption for the theatre staff. If anything, it's easier than getting a conventional kit ready. This system also allows me to tailor the operation to the patient's unique physiology, whereas with instruments I tended to perform the same operation every time on each patient." Patient Outcomes: Less pain, fewer revisions, and greater satisfaction post-surgery Over 680,000 people are currently waiting for a hip or knee replacement. Many of those have waited well over a year, living with chronic pain. More than 10 per cent of patients waiting for knee surgery in the UK say their quality of life is 'worse than death'.
The benefits of robotics-assisted surgery for patients are myriad and include significantly improved patient reported outcome measures (PROMs)9,10 † ‡ and shortened length of hospital stay11 ‡, there is evidence of an earlier return to an active lifestyle12 ‡.
Australia has been a leader in the field of robotics and navigation in orthopaedic surgery and the registry has demonstrated the benefits patients can expect such as fewer revisions and complications, and a shorter length of hospital stay with the patient able to be discharged in sub-24 hours. "The CORI system enables every patient to have a knee replacement that is shape matched and aligned to their specific anatomy. We know that outcomes aren't consistent in non-robotic surgeries and that one in five patients have issues following surgery. Our technology has evolved so that we can achieve a personalised fit to each individual patient," says Mr. Simon Tarry, Managing Director, UK, Ireland & Nordics, Smith+Nephew.

Innovation at Smith+Nephew
The CORI system is amongst the first technology to place the surgeon at the heart of the digital operating room. Surgeons can access the benefits of robotic surgery but still have full decision-making capability at each step of the operation.
This system is the first of several launches in technology and software over the next five years, demonstrating Smith+Nephew's commitment to improve surgical experience through digital and technology innovation across the patient pathway.
To learn more about Smith+Nephew's CORI surgical system please visit: www.robotics-surgery.com globe that have leveraged their core business strategies to drive positive social impact.

JOHNSON & JOHNSON
While the vaccine makers on last year's list were recognized for their unprecedented collaboration on fighting the coronavirus, this year's list highlights those that are helping expand access to COVID-19 vaccines around the world. Johnson & Johnson was honored to be included for its efforts to make available its Janssen COVID-19 vaccine, for which it received Emergency Use Authorization from the U.S. Food and Drug Administration in February.
To compile the prestigious list, Fortune evaluated companies on the impact they've made in addressing one or more of society's problems, the business results of those actions and the level of innovation involved. Also taken into consideration: how essential the company's initiative was to its overall business strategy.
A Commitment to Social Responsibility and Innovation: For more than a century, Johnson & Johnson has relied on a core set of values to guide every aspect of the way it does business.
When COVID-19 hit, the company was able to respond to the once-in-a-lifetime global health challenge by harnessing its capabilities, scientific expertise, global partnerships and experience in helping fight pandemics for over a century-and its 130,000-plus employees around the world mobilized with urgency to address the critical needs of families, communities and healthcare providers.
That sort of innovation and a commitment to social responsibility provide the foundation for Our Credo, the company's mission statement that compels everyone who works at Johnson & Johnson to put the needs and well-being of people who depend on its products and services first.

MÖLNLYCKE HEALTH CARE Granulox ® wins Prix Galien
Mölnlycke's haemoglobin spray Granulox ® has been awarded the prestigious Prix Galien for best new medical device in Belgium.
Granulox is Mölnlycke's innovative topical haemoglobin spray which facilitates oxygen diffusion for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
When Granulox is sprayed on a wound, highly purified haemoglobin is released. This binds with oxygen from the environment and diffuses through the exudate to supply oxygen to the base of the wound, supporting wound healing and improving patient outcomes.
Studies report that using Granulox results in shorter healing time, reduced pain scores and total cost savings for healthcare providers compared to standard of care.
• Twice as many chronic wounds healed at 8-16 weeks compared to standard of care • Time to heal diabetic foot ulcers 50% shorter than with standard of care • Treatment costs in diabetic foot ulcers at least 40% lower than with standard of care • More than 70% of patients reported lower average pain scores at four weeks than with standard of care in chronic wounds • 99% less slough in chronic wounds after 4 weeks compared to 33% with standard of care The Prix Galien is an annual prize which recognizes innovative medical devices which improve the human condition. The awards were created in France in 1970 by pharmacist Roland Mehl, in honour of Galen, the father of medical science and modern pharmacology. Receiving a Prix Galien is the highest accolade for the world's most innovative medicines and devices and is considered the pharmaceutical and medical industry's equivalent of the Nobel prize.
In their summation, the Prix Galien jury highlighted Mölnlycke's impressive dossier, video and clinical results. They commented that Granulox is used to treat a condition which presents a significant patient burden. It improves quality of life and contributes to interdisciplinary care, which will be important for the healthcare system of the future. Some members of the jury even described it as 'ingenious'! CEO Zlatko Rihter says: 'We're extremely honoured that Granulox has been recognized by the Prix Galien committee. We're also humbled to be in such prestigious company alongside businesses like Siemens Healthineers, BeWell Industries, Norgine, and Sunrise. This wouldn't have been possible without our Belgian team and our Granulox team.' Rob Claypoole, EVP Global Wound Care said: 'At Mölnlycke, we've long been convinced of the power of Granulox, but that it has now been recognized by the Nobel Prize for medical devices is further proof of just how innovative a product it is. We look forward to helping even more peoplewhether patients, caregivers, or clinicians -see the difference topical oxygen therapy can make in wound care.' Sabrina Suetens, Mölnlycke Business Director for Wound Care & General Manager for Benelux commented, 'I'm so incredibly proud of the entire team, and we really appreciate this award. The greatest reward, however, is the opportunity to make a difference in chronic wound patients' lives with such an easy-to-use product.' *References: www.molnlycke.com/productssolutions/granulox/ 3M 3M and UN Climate Change to address climate challenges, drive collective solutions Starting at COP26, new partnership will advance the Paris Agreement and UN Sustainable Development Goals 3M will highlight the unique challenges and opportunities manufacturers face in combatting climate change in a candid conversation with global peers at the Conference of the Parties (COP26) on Wednesday, Nov. 10 from 2:00-3:30pm GMT. The event will take place within the United Nations Climate Change (UNFCCC) pavilion as part of its new strategic partnership with 3M. In addition to featuring insights from international sustainability leaders, the conversation will be moderated by Sally Uren, CEO of Forum of the Future, a leading international sustainability non-profit. The discussion will be available for live and post-event public viewing on UNFCCC's YouTube channel.
"Through our established commitments, global manufacturing footprint and technology solutions, 3M is helping to drive positive impact on climate changeimpact that we can further expand and amplify through connections at COP26 and our new partnership with UNFCCC," said Gayle Schueller, 3M Senior Vice President and Chief Sustainability Officer. "By working with the UNFCCC and across its partnership network, we can share our insights as well as our challenges, emphasizing there is no singular approach to addressing climate change and encouraging new peers to join us in working toward a more sustainable future." 3M will work with the UNFCCC and its partnership network to drive collective action on climate change, social and environmental responsibility, and the UN Sustainability Development Goals (SDGs). Following COP26, 3M and UNFCCC will collaborate on engagements at key global climate events for the next three years.
Earlier this year, 3M announced it plans to invest $1 billion over the next 20 years to accelerate its environmental goals, including new commitments to achieve carbon neutrality by 2050, reduce water use 25% by 2030, enhance the quality of water returned to the environment after use in manufacturing, and reduce use of virgin fossil-based plastic by 125 million pounds (nearly 56,700 metric tons) by 2025. To help advance these goals, 3M has set interim targets to reduce water use 10% by 2022 and 20% by 2025 and decrease its carbon emissions 50% by 2030 and 80% by 2040 (using 2019 as a baseline). 3M has a strong history of reducing greenhouse gas emissions, and recently achieved Scope 1 and 2 absolute emissions levels that are more than 70% below a 2002 baseline. While continuing to drive immediate progress on these and its other existing sustainability commitments, 3M looks to broaden its positive impact through cross-sector collaboration at COP26 and its partnership with UNFCCC.
For more information on 3M's ongoing efforts to improve the environment, visit 3M.com/sustainability.